Thomas J. Schall, President and CEO at ChemoCentryx, Inc. (CCXI), sold 279,166 shares at $27.30 ($8.8M) on 2019-11-26, disclosed to the SEC on 2019-11-27.
Open-market sale of $8.8M CCXI by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.30 | 21,641 | $591K | 6.7% |
| 2 | $28.44 | 14,134 | $402K | 4.6% |
| 3 | $29.23 | 31,335 | $916K | 10.4% |
| 4 | $30.79 | 78,581 | $2.4M | 27.5% |
| 5 | $31.76 | 32,780 | $1.0M | 11.8% |
| 6 | $32.65 | 14,969 |
| $489K |
| 5.5% |
| 7 | $33.86 | 29,290 | $992K | 11.3% |
| 8 | $34.69 | 54,936 | $1.9M | 21.6% |
| 9 | $35.60 | 1,500 | $53K | 0.6% |
| Total | $31.55 avg | 279,166 | $8.8M | 100% |
| Filing → |
| IMRX | BUY | 2025-06-18 | $179K | — | Filing → |
| IMRX | BUY | 2024-03-25 | $7K | — | Filing → |
| CCXI | SELL | 2022-08-08 | $6.5M | — | Filing → |